Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Neuroblastoma 10Melanoma 8Neoplasm Metastasis 6Breast Neoplasms 6Ganglioneuroblastoma 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Carcinoma, Renal Cell 3Brain Neoplasms 3Uveal Melanoma 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia 2Gliosarcoma 2Glioma 2Carcinoma, Intraductal, Noninfiltrating 2Astrocytoma 2

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × Colony-Stimulating Factors × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT02728102 2024-05-07

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
203 enrolled 25 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT02593123 2023-01-23

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Virginia Commonwealth University

Phase 2 Completed
31 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00006184 2017-10-20

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled 10 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡